Gilead Sciences, Inc. $GILD Position Lessened by Capital Investment Advisors LLC

Capital Investment Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 70.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 106,239 shares of the biopharmaceutical company’s stock after selling 251,900 shares during the period. Capital Investment Advisors LLC’s holdings in Gilead Sciences were worth $11,792,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $215,000. Caxton Associates LLP bought a new stake in Gilead Sciences in the first quarter worth approximately $562,000. SCS Capital Management LLC bought a new stake in Gilead Sciences in the first quarter worth approximately $853,000. Finally, Advisory Alpha LLC increased its stake in shares of Gilead Sciences by 25.6% during the 1st quarter. Advisory Alpha LLC now owns 3,536 shares of the biopharmaceutical company’s stock worth $396,000 after purchasing an additional 721 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Citigroup boosted their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday. Mizuho upped their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Needham & Company LLC raised their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, The Goldman Sachs Group upped their target price on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.20.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 136,257 shares of company stock worth $16,855,192. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $120.67 on Friday. The company has a market cap of $149.71 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 0.66 and a beta of 0.33. The business has a 50 day moving average price of $123.24 and a 200 day moving average price of $117.41. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.